Alnylam Pharmaceuticals, Inc. vs Eli Lilly & Co.
ALNY vs LLY — side-by-side comparison from reported financials. ALNY leads 4, LLY leads 6 of 10 comparable metrics.
Alnylam Pharmaceuticals, Inc.
ALNY · Healthcare
$232.60+3.59%Strong
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
| Metric | ALNY | LLY |
|---|---|---|
| Price | $232.60 | $1 177.20 |
| Market cap | $31.1B | $1.05T |
| Revenue (TTM) | $4.80B | $79.7B |
| Revenue growth | +53.0% | +31.7% |
| Net margin | 16.8% | 33.5% |
| Free cash flow | $794M | $18.2B |
| Net cash (debt) | — | ($35.2B) |
| 1-year price return | -49.1% | +37.6% |
| P/E | 38.5 | 41.6 |
| P/E vs own history (cheap-side %) | 92% | 88% |
| Dividend yield | — | 0.52% |
| Return on equity | 94% | 93% |
| Altman Z-score | 4.40 | 7.10 |
| CV checks passed | 8 of 10 | 11 of 10 |
| Employees | 2,500 | 50,000 |
Full résumé-style profiles: ALNY CV · LLY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.